

## Myanmar Support for Pneumococcal Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Myanmar							
<b>2. Grant number:</b> 1721-MMR-12b-X							
<b>3. Date of Decision Letter:</b> 19 December 2016							
<b>4. Date of the Partnership Framework Agreement:</b> 4 April 2014							
<b>5. Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine							
<b>6. Vaccine type:</b> Pneumococcal							
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV10), 2 dose(s) per vial , LIQUID							
<b>8. Programme duration<sup>1</sup>:</b> 2016 - 2021							
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement)							
	2016	2017	2018	2019	2020	2021	Total <sup>2</sup>
Programme Budget (US\$)	19,225,500 <sup>3</sup>	4,576,000	9,314,000	9,224,500	9,612,000	9,589,500	61,541,500
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable							
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>4</sup>							
Type of supplies to be purchased with Gavi funds in each year	2016			2017			
Number of Pneumococcal vaccines doses				1,353,200			
Annual Amounts (US\$)	19,225,500 <sup>5</sup>			4,576,000			
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.							
<b>13. Self-procurement:</b> Not applicable							

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

**14. Co-financing obligations:** Reference code: 1721-MMR-12b-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017	2018	2019	2020
Number of vaccine doses	107,800	250,400	277,600	319,800
Number of AD syringes	94,600			
Number of safety boxes	1,050			
Value of vaccine doses (US\$)	328,202			
Total co-financing payments (US\$) (including freight)	336,500	783,000	869,500	1,001,500

**15. Operational support for campaigns:** Not applicable

**16. Additional reporting requirements:** Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**17. Financial clarifications:** The country shall address any recommendations, prioritised needs or strategic actions as described in the High Level Review Panel Report (October 2016).

**18. Other conditions:** Not applicable.

Signed by,

**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
19 December 2016

  
Barry Greene  
Managing Director  
Finance & Operations  
The GAVI Alliance

20 December 2016